EA028929B1 - Аналоги глюкагоноподобного пептида-2 (glp-2) - Google Patents

Аналоги глюкагоноподобного пептида-2 (glp-2) Download PDF

Info

Publication number
EA028929B1
EA028929B1 EA201491934A EA201491934A EA028929B1 EA 028929 B1 EA028929 B1 EA 028929B1 EA 201491934 A EA201491934 A EA 201491934A EA 201491934 A EA201491934 A EA 201491934A EA 028929 B1 EA028929 B1 EA 028929B1
Authority
EA
Eurasian Patent Office
Prior art keywords
absent
analogue
рго
acre
specified
Prior art date
Application number
EA201491934A
Other languages
English (en)
Russian (ru)
Other versions
EA201491934A1 (ru
Inventor
Расмус Джаст
Кирстен Линдегард Бовбьерг
Дитте Рибер
Уэйн Шон Рассел
Original Assignee
Зилэнд Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зилэнд Фарма А/С filed Critical Зилэнд Фарма А/С
Publication of EA201491934A1 publication Critical patent/EA201491934A1/ru
Publication of EA028929B1 publication Critical patent/EA028929B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Insects & Arthropods (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
EA201491934A 2012-05-03 2013-05-03 Аналоги глюкагоноподобного пептида-2 (glp-2) EA028929B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261642447P 2012-05-03 2012-05-03
US201361785852P 2013-03-14 2013-03-14
PCT/EP2013/059320 WO2013164484A1 (en) 2012-05-03 2013-05-03 Glucagon-like-peptide-2 (glp-2) analogues

Publications (2)

Publication Number Publication Date
EA201491934A1 EA201491934A1 (ru) 2015-07-30
EA028929B1 true EA028929B1 (ru) 2018-01-31

Family

ID=48428462

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491934A EA028929B1 (ru) 2012-05-03 2013-05-03 Аналоги глюкагоноподобного пептида-2 (glp-2)

Country Status (13)

Country Link
US (3) US9453064B2 (enExample)
EP (1) EP2844670B1 (enExample)
JP (1) JP6298044B2 (enExample)
KR (1) KR20150006052A (enExample)
CN (1) CN104540850B (enExample)
AU (1) AU2013255752B2 (enExample)
BR (1) BR112014027345A2 (enExample)
CA (1) CA2872315A1 (enExample)
EA (1) EA028929B1 (enExample)
IN (1) IN2014DN09782A (enExample)
MX (1) MX356958B (enExample)
TR (1) TR201802689T4 (enExample)
WO (1) WO2013164484A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576260A (en) 2006-11-08 2012-04-27 Zealand Pharma As GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
BR112015001451B1 (pt) 2012-07-23 2022-03-29 Zealand Pharma A/S Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
MX368436B (es) 2013-10-17 2019-10-03 Zealand Pharma As Analogos de glucagon acilados.
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086731A1 (en) * 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2883345T3 (es) 2014-10-29 2021-12-07 Zealand Pharma As Compuestos agonistas del GIP y métodos
US20180280480A1 (en) * 2014-10-31 2018-10-04 Gubra Aps Compositions and peptides having dual glp-1r and glp-2r agonist activity
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
PL3393496T3 (pl) 2015-12-23 2024-04-22 The Johns Hopkins University Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
JP6700150B2 (ja) * 2016-10-03 2020-05-27 東京エレクトロン株式会社 パーティクル捕集装置、パーティクル捕集方法、およびパーティクル捕集システム
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
KR102587196B1 (ko) * 2016-12-09 2023-10-10 질랜드 파마 에이/에스 Glp-1/glp-2 이중 효능제
CA3043151A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104559A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
EP4424362A3 (en) * 2017-06-16 2024-11-27 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
KR102825098B1 (ko) 2017-11-06 2025-06-26 다케다 야쿠힌 고교 가부시키가이샤 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
WO2020165900A1 (en) 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs
WO2020249778A1 (en) 2019-06-14 2020-12-17 Zealand Pharma A/S Pharmaceutical parenteral composition of dual glp1/2 agonist
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
CN111329995B (zh) * 2020-02-18 2022-11-11 河南中医药大学 Glp-2类似物在制备防治pd药物中的应用及防治pd的药物
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
CA3173353A1 (en) * 2020-04-03 2021-10-07 Jin Bong Lee Pharmaceutical composition for preventing or treating mucositis induced by radiotherapy, chemotherapy, or combination thereof, comprising glp-2 derivatives or long-acting conjugate of same
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
IL298964A (en) 2020-06-09 2023-02-01 Vectivbio Ag Manufacture, formulation and dosing of apraglutide
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
KR20250069663A (ko) 2022-09-19 2025-05-19 질랜드 파마 에이/에스 병용 요법
CN116478269A (zh) * 2023-04-28 2023-07-25 成都奥达生物科技有限公司 一种长效替度鲁肽化合物
CN118146350B (zh) * 2024-03-13 2024-10-22 北京泽勤生物医药有限公司 Glp-2肽类似物的制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070251A1 (en) * 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2011160630A2 (en) * 2010-06-23 2011-12-29 Zealand Pharma A/S Glucagon analogues
WO2012158965A2 (en) * 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP4064460B2 (ja) 1996-03-01 2008-03-19 ノボ ノルディスク アクティーゼルスカブ 食欲抑制性ペプチドを含む医薬組成物の用途
CN1268640C (zh) 1996-04-12 2006-08-09 1149336安大略公司 胰高血糖素样肽－2的类似物
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US20020025933A1 (en) 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
ATE290014T1 (de) 1996-09-09 2005-03-15 Zealand Pharma As Festphasen-peptidsynthese
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
AU746633B2 (en) 1997-05-16 2002-05-02 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
US6803357B1 (en) 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
EP1950224A3 (en) 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO1999058144A1 (en) 1998-05-11 1999-11-18 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
HUP0200297A3 (en) 1999-03-17 2002-09-30 Novo Nordisk As Method for acylating peptides and the glutaminic acid derivatives as acylating agents
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20030040478A1 (en) 1999-12-08 2003-02-27 Drucker Daniel J Chemotherapy treatment
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
ATE396738T1 (de) 2000-09-18 2008-06-15 Sanos Bioscience As Verwendung von glp-2-peptiden
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
WO2002066511A2 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
EP1542712A2 (en) 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
PL376223A1 (en) * 2002-10-14 2005-12-27 Novo Nordisk As Glucagon - like peptide - 2 variants
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
CN1705681A (zh) * 2002-10-14 2005-12-07 诺沃挪第克公司 Glp－2化合物、制剂及其用途
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
WO2005082404A2 (en) * 2004-02-27 2005-09-09 Novo Nordisk A/S Glp-2 derivatives modified by lipophilic substituents
EP1809318B1 (en) 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
CN101171262B (zh) 2005-05-04 2012-06-27 西兰制药公司 胰高血糖素样肽-2(glp-2)类似物
NZ576260A (en) 2006-11-08 2012-04-27 Zealand Pharma As GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070251A1 (en) * 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2011160630A2 (en) * 2010-06-23 2011-12-29 Zealand Pharma A/S Glucagon analogues
WO2012158965A2 (en) * 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B.A. MOORE ET AL.: "GLP-2 Receptor Agonism Ameliorates Inflammation and Gastrointestinal Stasis in Murine Postoperative Ileus", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 333, no. 2, 1 May 2010 (2010-05-01), pages 574-583, XP055073554, ISSN: 0022-3565, DOI: 10.1124/jpet.109.161497, the whole document *
DACAMBRA M.P. ET AL.: "Structural determinants for activity of glucagon-like peptide-2", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 30, 1 August 2000 (2000-08-01), pages 8888-8894, XP002293748, ISSN: 0006-2960, DOI: 10.1021/BI000497P, whole document, especially figure 1 *
MI JIN MOON ET AL.: "Tyr(1) and Ile(7) of Glucose-Dependent Insulinotropic Polypeptide (GIP) Confer Differential Ligand Selectivity toward GIP and Glucagon-like Peptide-1 Receptors", MOLECULES AND CELLS, SEOUL, KR, vol. 30, no. 2, 31 August 2010 (2010-08-31), pages 149-154, XP002662065, ISSN: 1016-8478, DOI: 10.1007/S10059-010-0100-5 [retrieved on 2010-08-19], the whole document *

Also Published As

Publication number Publication date
CA2872315A1 (en) 2013-11-07
BR112014027345A2 (pt) 2019-09-03
IN2014DN09782A (enExample) 2015-07-31
US10253080B2 (en) 2019-04-09
TR201802689T4 (tr) 2018-03-21
JP6298044B2 (ja) 2018-03-20
EA201491934A1 (ru) 2015-07-30
CN104540850B (zh) 2018-05-18
AU2013255752B2 (en) 2017-11-09
US20180298077A1 (en) 2018-10-18
EP2844670A1 (en) 2015-03-11
US9969787B2 (en) 2018-05-15
US20150125431A1 (en) 2015-05-07
AU2013255752A1 (en) 2014-12-18
US9453064B2 (en) 2016-09-27
JP2015517299A (ja) 2015-06-22
HK1208238A1 (en) 2016-02-26
WO2013164484A1 (en) 2013-11-07
KR20150006052A (ko) 2015-01-15
MX2014013319A (es) 2015-07-06
MX356958B (es) 2018-06-20
US20160355563A1 (en) 2016-12-08
CN104540850A (zh) 2015-04-22
EP2844670B1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
EA028929B1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
US8163696B2 (en) Treatment of inflammatory bowel disease using glucagon-like-peptide-2 (GLP-2) analogues
AU2007319066B2 (en) Selective glucagon-like-peptide-2 (GLP-2) analogues
ES2620111T3 (es) Análogos de glucagón
AU2017371516C1 (en) Acylated GLP-1/GLP-2 dual agonists
JP2020045362A (ja) グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
US20180009849A1 (en) Ghrelin analogues
US20190330295A1 (en) Glucagon-like-peptide-2 (glp-2) analogues
HK1208238B (en) Glucagon-like-peptide-2 (glp-2) analogues

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU